Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
01 déc. 2022 08h00 HE
|
Vaxart, Inc.
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to...
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
22 nov. 2022 08h30 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
08 nov. 2022 16h01 HE
|
Vaxart, Inc.
Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with...
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
20 oct. 2022 08h30 HE
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
10 oct. 2022 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief...
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 08h30 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and...
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
01 sept. 2022 06h30 HE
|
Vaxart, Inc.
— Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive...
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
31 août 2022 16h30 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II...
Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer
31 août 2022 08h30 HE
|
Vaxart, Inc.
Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies SOUTH SAN...
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
25 août 2022 16h05 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors,...